Article as featured in the Financieel Dagblad (Financial Times), 29 November 2024 (link)
VectorY’s Clinical Milestone and the Shift Toward Experimentally-Validated Promoters
The first patient dosing in VectorY Therapeutics’ PIONEER-ALS trial marks a definitive shift in gene therapy, moving past the “conservative” reliance on blunt viral promoters and the “digital guesses” of AI. While many rely on algorithms built from incomplete and insensitive data, VTx-002 is powered by an Annogen genome-derived promoter discovered through rigorous, large-scale experimental validation. This milestone proves that true therapeutic precision isn’t predicted in a black box—it is found by interrogating the genome directly to deliver the biological truth required for the clinic.
